Eli Lilly Releases Study Showing Zepbound May Reduce Healthcare Costs
Eli Lilly recently published results from a real-world study on its GLP-1 weight-loss medication, Zepbound (tirzepatide), showing that patients using the drug incurred significantly lower healthcare costs compared to those not taking it. The findings suggest up to 38% reduction in medical expenses after one year due to fewer hospital admissions and emergency visits. The study could help Eli Lilly make a stronger case for broader insurance coverage of Zepbound, which currently has limited third-party payer support due to high out-of-pocket costs. If insurers expand coverage based on these results, demand for the drug is expected to rise significantly, potentially boosting sales and reducing patients' reliance on cheaper compounded alternatives. Eli Lilly's recent financial performance remains strong, with Q2 revenue up 48% year-over-year to $23 billion, driven largely by Mounjaro (also tirzepatide) and Zepbound. The company continues to benefit from the growing GLP-1 market despite ongoing challenges in securing insurance coverage for its weight-loss therapies.
